PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab.

被引：3

作者：

Ray-Coquard, Isabelle Laure

Harter, Philipp

Martin, Antonio Gonzalez

Cropet, Claire

Pignata, Sandro

Fujiwara, Keiichi

Marth, Christian

Vergote, Ignace

Mirza, Mansoor Raza

Colombo, Nicoletta

Rosenberg, Per

Maenpaa, Johanna Unelma

lauraine, Eric PujaDe

机构：

[1] GINECO Grp, Lyon, France

[2] Ctr Leon Berard, Lyon, France

[3] AGO Germany, Essen, Germany

[4] GEICO, Madrid, Spain

[5] MD Anderson Canc Ctr Madrid, Madrid, Spain

[6] GINECO, Lyon, France

[7] MITO, Naples, Italy

[8] GOTIC, Hidaka, Japan

[9] AGO Austria, Innsbruck, Austria

[10] Univ Hosp Leuven, BGOG, Leuven, Belgium

[11] Copenhagen Univ Hosp, NSGO, Copenhagen, Denmark

[12] MANGO, Milan, Italy

[13] NSGO, Linkoping, Sweden

[14] Univ Hosp, Linkoping, Sweden

[15] NSGO, Tampere, Finland

[16] GINECO, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.TPS5605

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS5605

引用

页数：3

共 50 条

[41] MONO-OLA1: A randomized, phase III study of olaparib maintenance monotherapy in patients with BRCA wild-type advanced ovarian cancer following response to first-line platinum-based chemotherapy
Saevets, Valeriya
Yin, Rutie
Zhu, Jianqing
Chen, Chris
Zhang, Jing
Ah-See, Mei-Lin
Bchir, M. B.
Wu, Xiaohua
GYNECOLOGIC ONCOLOGY, 2022, 166 : S172 - S172
[42] ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA(sic)-nonmutated advanced epithelial ovarian cancer
Fujiwara, K.
Vergote, I. B.
Sehouli, J.
Salutari, V.
Zola, P.
Madry, R.
Wenham, R. M.
Korach, J.
Pautier, P.
Cibula, D.
Lheureux, S.
Hasegawa, K.
Kim, B-G.
Lai, C-H.
Gonzalez-Martinez, A.
Liu, Q.
Keefe, S. M.
Puglisi, M.
Topuz, S.
ANNALS OF ONCOLOGY, 2019, 30
[43] Olaparib plus /- bevacizumab versus bevacizumab plus fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX plus bevacizumab: Phase III LYNK-003 study.
Mayo, Carlos Alberto
Gurary, Ellen B.
Marinello, Patricia
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[44] Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
Kurtz, Jean-Emmanuel
Pujade-Lauraine, Eric
Oaknin, Ana
Belin, Lisa
Leitner, Katharina
Cibula, David
Denys, Hannelore
Rosengarten, Ora
Rodrigues, Manuel
de Gregorio, Nikolaus
Garcia, Jeronimo Martinez
Petru, Edgar
Kocian, Roman
Vergote, Ignace
Pautier, Patricia
Schmalfeldt, Barbara
Gaba, Lydia
Polterauer, Stephan
Reynier, Marie-Ange Mouret
Sehouli, Jalid
Churruca, Cristina
Selle, Frederic
Joly, Florence
D'Hondt, Veronique
Bultot-Boissier, Emilie
Lebreton, Coriolan
Lotz, Jean-Pierre
Largillier, Remy
Heudel, Pierre-Etienne
Heitz, Florian
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (30) : 4768 - +
[45] Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.
Kindler, Hedy L.
Hammel, Pascal
Reni, Michele
Van Cutsem, Eric
Macarulla, Teresa
Hall, Mercade Michael J.
Park, Joon Oh
Hochhauser, Daniel
Arnold, Dirk
Oh, Do-Youn
Reinacher-Schick, Anke C.
Tortora, Giampaolo
Alguel, Hana
O'Reilly, Eileen Mary
McGuinness, David
Cui, Karen
Schlienger, Katia
Locker, Gershon Y.
Golan, Talia
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
[46] Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial
Colombo, N.
Gantzer, J.
Ataseven, B.
Cropet, C.
Scambia, G.
Herrero, A.
Sevelda, P.
Kobayashi, H.
Vuylsteke, P.
Mirza, M. R.
Priou, F.
Buderath, P.
Pisano, C.
Lainez, N.
Guillemet, C.
Burges, A.
Sverdlin, R.
El-Balat, A.
Raban, N.
Ray-Coquard, I. L.
ANNALS OF ONCOLOGY, 2020, 31 : S614 - S614
[47] OVARIO, A Phase 2 Study of Niraparib plus Bevacizumab in Advanced Ovarian Cancer (OC) Following Front-Line Platinum-Based Chemotherapy (CT) with Bevacizumab (bev): Updated Analysis
Hardesty, Melissa. M.
Grabowski, Jacek
Krivak, Thomas
Wright, Gail. S.
Hamilton, Erika
Fleming, Evelyn. L.
Belotte, Jimmy
Keeton, Erika
Wang, Ping
Clements, Aine
Gray, Heidi. J.
Konecny, Gottfried. E.
Moore, Richard. G.
Richardson, Debra
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 113 - 113
[48] SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC
Cappuzzo, F.
Ciuleanu, T.
Stelmakh, L.
Cicenas, S.
Szczesna, A.
Juhasz, E.
Gonzalez, E. Esteban
Molinier, O.
Klingelschmitt, G.
Giaccone, G.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[49] ATALANTE (ENGOT-ov29): A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab.
Kurtz, Jean Emmanuel
Marth, Christian
Oaknin, Ana
Asselain, Bernard
Baumann, Klaus H.
Cibula, David
Vergote, Ignace
Levy, Tally
Pujade-Lauraine, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[50] Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
Robert, Nicholas J.
Saleh, Mansoor N.
Paul, Devchand
Generali, Daniele
Gressot, Laurent
Copur, Mehmet S.
Brufsky, Adam M.
Minton, Susan E.
Giguere, Jeffrey K.
Smith, John W., II
Richards, Paul D.
Gernhardt, Diana
Huang, Xin
Liau, Katherine F.
Kern, Kenneth A.
Davis, John
CLINICAL BREAST CANCER, 2011, 11 (02) : 82 - 92

← 1 2 3 4 5 →